Advertisement
Advertisement
U.S. markets open in 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
246.72+5.87 (+2.44%)
At close: 04:00PM EDT
245.27 -1.45 (-0.59%)
Pre-Market: 08:26AM EDT
Advertisement
Sign in to post a message.
  • s
    scott
    July this will be back over $260 and touching $280! If you own Pharm you will recover quickly as the money flow reverses for one of the few insulated industries in the market. I WOULDN'T want to own retail like #FIVE who will be down 50% from where it was a few weeks ago. Owning, promoting something like retail is almost as bad as shoring GME@$4! Hold tight and consider yourself lucky! $280 by July and several data readouts this year!
  • j
    john
    There was an article earlier this week in Seeking Alpha that mentioned VRTX possibly buying CRSP out... what do you guys think about that ? Good move or bad ?
  • T
    Thirdmeinvestor
    $VRTX is drawing a cup-and-handle chart. It is a bullish chart. The share price will go up soon. I personally would not sell below 300. When CTX-001, VX-147, and VX-548 are marketed some years from now, the share price could more than double from current prices.
  • j
    john
    I do think we will bounce back quickly... in 3-4 months new highs IMHO
    Bullish
  • t
    thomas
    some analyst comments on todays news After Vertex announced the FDA placed a clinical hold on VX-880, despite the Independent Data Monitoring Committee recommending advancement to Part B, or full dose, in the Phase 1/2 study, Piper Sandler analyst Do Kim said he believes the hold could be related to the number of patients in Part A. The part of the study evaluated two patients at half VX-880 target doses, but dose escalation normally requires three patients per level, said Kim, who also called patient one having achieved insulin independence at Day 270 "a significant achievement" for the VX-880 program. Kim has a Neutral rating and $249 price target on Vertex shares. Jefferies analyst Michael Yee said that “the diabetes program has a slight setback today but we’d buy the dip since it’s not the primary thesis to the story.” He noted that the cell therapy holds usually last four to five months.

    Truist's Robyn Karnauskas shared similar views and argued that the clinical hold was not a negative.

    “We’re defending the stock and recommend owning within the group as it is one of the cleaner, growth stories in our view that continues to beat and raise on Trikafta uptake in other geographies
  • J
    JEFFREY P
    If I was thinking about adding shares in VRTX today seems like the perfect day. When the clinical hold on the VX 880 trial is lifting in the next assessment of the fully dosed patient in the next 2 months, the decision on admisnitstering an amount greater 50% of the planned dose wil be either modified or left in it's original protocol. The FDA probably is concerned about the possibility of theoretical hypoglycemic events from failure of glucose autoregulation of the transplanted stem cells in the higher dose of VX 880 since patient one achieved insulin independence at day 270. while patient 3 who received the higher dose has not demonstrated any hypoglycemic events at day 29 the FDA probably wants to observe the effects of the higher dose on this patinet for a few months to see if autoregulation permits insulin indepndence sooner without hypoglycemia. The market hates uncertainty, but clearly an optimal cell dose will be determined and the FDA will not have much reason to delay resinstituting the study once response to treatment of patient three is deternined to be safe. If needed of course, the amount of stem cells administered in the protocol could be reduced somewhat. In the meantime, the program reamins in tact albeit termporarily slowed down, but continues to hold great promise for the cure of Type 1 DM potentially with a device or modification of the stem cells that eventually will elimnate the need for immunsuppression post transplant. Great buying opportuinity today especially after the news that ABBV CF triplet in proof of concept trial failed and will not be advanced, leaving trikafta as the undisputed standard of care for 90% of CF patients.
  • J
    Jeffrey
    Another buying opportunity before the FDA releases the hold on VX 880 and the stock breaks out to new highs
  • y
    y
    This is the risk of investing in pharma stock. That said, FDA isn't rejecting VX 880. It just doesn't think the dose should be increased in the next stage of the test. Based on the positive results so far, it appears the trial will resume eventually.
  • J
    JEFFREY P
    VRTX Stock acting very postivie this morning as ABBV is finishing it's first quarter investor confernce call. I suspect questions about the AABV clinical trial testing it's triplet for CF were discussed and the results are either still delayed or are not competitive with Trikafta?
  • t
    thomas
    Abbvie Inc (ABBV) - Abbvie Says Its Triple Combination Drug for Cystic Fibrosis Failed to Meet Co's Criteria for Developing It Further - Conf Call.
  • T
    Thirdmeinvestor
    [[ ... RBC Capital Markets analyst Brian Abrahams wrote in a note Monday that the FDA hold is “somewhat cryptic given the favorable disclosed efficacy/safety profile.”
    “Unless there is a major concern not being disclosed, it would not seem that this hurdle is insurmountable, and it could potentially be addressed with additional follow-up,” Abrahams wrote.
    Jefferies analyst Michael Yee said the hold was a slight setback and “we’d buy the dip since it’s not the primary thesis to the story — and these holds tend to get lifted in due course and back on track.”]]

    https://www.barrons.com/articles/vertex-pharmaceuticals-vrtx-fda-clinical-hold-diabetes-treatment-51651503277?mod=Searchresults
  • J
    Jeffrey
    So now the competition for Vrtx in CF is from ABBV which has been reduced to a backup corrector compound untested in CF that will not begin proof of concept
    Clinical trials until 2023 and a start up company called Scion who has a “novel target” that in the past has.been deemed “undruggable “, After failures attempted by much larger better funded and experienced labs e.g. Pfizer
    It appears to me all the
    Analysts predicting loss of Vrtx CF market share from competition from ABBV need to recalibrate their rating and price targets for VRTX as CTX001 and VX 121/tezacaftor/VX 561 approaches regulatory approval later this year.
    As non opiate pain meds and APOL-1 mediated renal disease treated with VX 147 start pivotal late stage trials later this year, a neutral rating with Price targets well below current market value make those analysts negative on Vrtx seem very out of touch with the true value that Vrtx deserves.
  • J
    JEFFREY P
    Whats next
    Earnings next week, with expanding growth of international sales with recent approvals for reimbursement of trikafter additional countries as well as expanded label for use of drug in younger pateints. More importantly, investor call following the earninigs release will highlight pipeline progress with updates on when data expected from phase 2 and phase 3 trials in multiple clinical trials which highlight progress in the triple drug regiemn that involves once daily dosing to potenetially treat 90 % of all patient's with CF and initiation of clinical trials using treatement developed with Moderna to provide treatment for the last 10 % of CF patients not able to be helped with CFTR modulators, and the multiple drug trials in progress to provide breakthrough treatments for APOL -1 renal disease, Sickle cell anemia, Thallasemia, Type 1 DM, and pain, We may hear about pre clinical trial treatment candidates being advanced into the clinic to treat neuropathic and chronic pain, Duchenne's MD and AATD as well. The future has not looked brighter for Vertex.
  • R
    Red Eye Stocks
    Amazing long term
  • M
    Margaux
    I see the last earnings as very positive. Why does the market act as if it was a disappointment? Because of the miss?
  • R
    Ron
    Cathy woods is selling that means this stock will likely go up!
  • M
    Mike
    Man, I really broke this stock, huh
  • s
    scott
    There is a failure on this board who goes by ‘Whiskers’ (Where’sJedd) and when he’s not in denial about his precious #FIVE crashing below $150 he spends his time, cyberstalking, lying about how much money he has and how many shares of FIVE he owns. His ‘buy it all price’ for FIVE was $185…and he said sell VRTX at $205 to do so. meanwhile I called FIVE to hit $150 FIVE and VRTX to hit $300.

    FIVE hasn’t seen $185 since he endorsed ‘buying it all’ and now it’s channel bound to $150 while VRTX was within single digits of $300. By late June or early July we’ll be there again while FIVE will continue to struggle to hold $150. Haha I win!
  • R
    Robert
    Pulled back a little which is not uncommon going into earnings, but this is uncommon considering the pipeline development. Consider the presentation our CEO gave to Collins and ask yourself if you are not even more enthusiastic about the outlook. I believe we are nowhere near the run in this cycle. I am tempted to add some options to my position.
Advertisement
Advertisement